RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
-17.9%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$4.58B
AUM Growth
+$4.58B
(-19%)
Cap. Flow
+$268M
Cap. Flow
% of AUM
5.84%
Top 10 Holdings %
Top 10 Hldgs %
44.83%
Holding
107
New
10
Increased
11
Reduced
7
Closed
11
Top Buys
| 1 |
Biogen
BIIB
|
$153M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
$68.6M |
| 3 |
AN2 Therapeutics
ANTX
|
$55.3M |
| 4 |
Natera
NTRA
|
$53.3M |
| 5 |
Vera Therapeutics
VERA
|
$46.2M |
Top Sells
| 1 |
Novavax
NVAX
|
$103M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
$61.3M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
$54.2M |
| 4 |
C4 Therapeutics
CCCC
|
$44.4M |
| 5 |
TG Therapeutics
TGTX
|
$42M |
Sector Composition
| 1 | Healthcare | 97.97% |
| 2 | Financials | 0.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
MacroGenics
MGNX
$112M
| $53.8M | 1.17% |
6,103,594
| – | – |
|
|
27
Natera
NTRA
$23.1B
| $53.3M | 1.16% |
+1,310,289
| New | +$53.3M |
|
28
Instil Bio
TIL
$182M
| $52.4M | 1.14% |
4,870,793
| – | – |
|
|
29
Novavax
NVAX
$1.21B
| $51M | 1.11% |
692,794
-1,405,000
| -67% | -$103M |
|
|
KNTE
30
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $48M | 1.05% |
4,264,144
+671,092
| +19% | +$7.56M |
|
|
31
Vera Therapeutics
VERA
$1.38B
| $46.2M | 1.01% |
+1,966,084
| New | +$46.2M |
|
|
PRDS
32
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $44.6M | 0.97% |
6,175,038
+3,048,000
| +97% | +$22M |
|
|
ICVX
33
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $42M | 0.92% |
5,963,565
+184,218
| +3% | +$1.3M |
|
34
Tenaya Therapeutics
TNYA
$184M
| $41.8M | 0.91% |
3,551,508
| – | – |
|
35
Geron
GERN
$893M
| $41M | 0.89% |
30,126,299
| – | – |
|
36
EyePoint Pharmaceuticals
EYPT
$797M
| $41M | 0.89% |
3,370,506
| – | – |
|
37
Avidity Biosciences
RNA
$5.99B
| $40M | 0.87% |
2,167,391
+1,743,775
| +412% | +$32.2M |
|
38
Acumen Pharmaceuticals
ABOS
$82.4M
| $38.2M | 0.83% |
9,770,773
| – | – |
|
39
RxSight
RXST
$370M
| $37.8M | 0.82% |
3,052,796
| – | – |
|
40
PMV Pharmaceuticals
PMVP
$74.2M
| $35.6M | 0.78% |
1,710,265
| – | – |
|
41
Design Therapeutics
DSGN
$315M
| $35.3M | 0.77% |
2,186,636
| – | – |
|
42
Rocket Pharmaceuticals
RCKT
$354M
| $33.4M | 0.73% |
2,107,149
| – | – |
|
|
CNTA
43
Centessa Pharmaceuticals
CNTA
$2.25B
| $32.1M | 0.7% |
3,577,094
| – | – |
|
44
Guardant Health
GH
$8.41B
| $31.6M | 0.69% |
+476,380
| New | +$31.6M |
|
45
Aclaris Therapeutics
ACRS
$209M
| $31.3M | 0.68% |
+1,817,808
| New | +$31.3M |
|
|
CCXI
46
DELISTED
ChemoCentryx, Inc.
CCXI
| $29M | 0.63% |
+1,155,964
| New | +$29M |
|
47
KalVista Pharmaceuticals
KALV
$678M
| $28.5M | 0.62% |
1,930,322
| – | – |
|
|
LIAN
48
DELISTED
LianBio American Depositary Shares
LIAN
| $28.4M | 0.62% |
7,655,015
| – | – |
|
49
Dyne Therapeutics
DYN
$1.92B
| $27M | 0.59% |
2,805,045
| – | – |
|
|
VRNA
50
Verona Pharma
VRNA
$9.16B
| $25.4M | 0.56% |
5,100,000
| – | – |
|